Archives
How CSN2 Targeting Raised Rabbit Pharming Yields
2026-11-09
A 2025 study used targeted insertion at the rabbit CSN2 locus to place a tdTomato reporter under an endogenous milk-protein regulatory environment. The resulting milk concentrations were substantially above historical rabbit pharming benchmarks, but the evidence remains centered on a reporter protein, a small number of animals, and cross-study comparisons rather than a matched manufacturing evaluation.
What the Cancer Nanomedicine Evidence Shows
2026-11-09
Liu and colleagues’ preclinical study supports a coordinated calcium-lactate nanomedicine mechanism involving bufalin, CD47-directed CRISPR/Cas9 ribonucleoprotein delivery, tumor-cell stress, and macrophage-mediated immunity. The findings are biologically coherent but remain model-dependent, and they do not establish clinical efficacy or assign the nanomedicine’s effects to an associated PCR reagent.
How CSN2 Targeting Raised Rabbit Pharming Yields
2026-11-08
A literature-focused analysis of a targeted rabbit line that used the endogenous CSN2 regulatory locus to drive recombinant protein expression. The study reports substantially higher milk concentrations than historical conventional-transgenic benchmarks, while leaving important questions about generalizability, therapeutic-protein performance, and production consistency.
Laurdan GP and Dynamic Lipid-Nanoparticle Interfaces
2026-11-07
Laurdan generalized polarization is a comparative readout of membrane hydration and lipid packing. In dynamic lipid nanoparticles, it can clarify physical-state changes while remaining distinct from direct evidence of PEG cleavage, cellular uptake, mRNA expression, or therapeutic benefit.
Targeted Expression Raises Rabbit Pharming Yields
2026-11-06
A 2025 study tested whether placing a recombinant reporter gene at the rabbit CSN2 milk-protein locus could overcome the variable expression associated with conventional transgenesis. The reported milk concentrations were substantially higher than historical rabbit pharming benchmarks, but the evidence remains centered on a reporter protein and a small number of homozygous animals.
When Context Changes a Juvenile-Hormone Result
2026-11-06
The same juvenile-hormone-related readout can represent endogenous biosynthesis, receptor-pathway activation, or a downstream developmental consequence. Evidence from migratory locusts shows why model, comparator, developmental stage, and measurement choice determine what a result can legitimately establish.
Why CSN2 Targeting Raises Rabbit Milk Yields
2026-11-05
A targeted rabbit line used the endogenous CSN2 milk-protein locus to drive recombinant tdTomato expression, producing substantially higher reported milk concentrations than conventional pharming examples. The result supports a locus-and-promoter mechanism, while the small number of animals and cross-study comparisons limit generalization.
Why the CSN2 Locus Raises Rabbit Pharming Yield
2026-11-05
A mechanistic analysis of how targeted integration at the rabbit CSN2 milk-protein locus may increase recombinant protein concentration, what the reported tdTomato results establish, and where cross-study comparisons remain limited.
CSN2-Targeted Rabbit Pharming: What the Data Show
2026-11-04
A 2025 study reported markedly higher milk concentrations of a fluorescent recombinant protein from rabbits carrying a targeted insertion at the endogenous CSN2 locus. The result supports a promising expression strategy, but the evidence remains limited by the small number of high-yield animals, the use of a reporter protein, and indirect comparisons with conventional transgenic lines.
What High-Yield Rabbit Pharming Evidence Shows
2026-11-04
A targeted rabbit line produced unusually high milk concentrations of a reporter protein, but the evidence is an early feasibility result rather than a controlled demonstration that the strategy generalizes to therapeutic proteins or manufacturing.
Why CSN2 Targeting Raises Rabbit Milk Yield
2026-11-03
A mechanistic analysis of how targeted insertion at the rabbit CSN2 locus may improve recombinant protein expression, what the reported 15–20 g/L tdTomato concentration establishes, and why the result remains a proof of concept rather than a general production benchmark.
What a CSN2 Knock-In Reveals About Rabbit Pharming
2026-11-03
A literature-focused analysis of a 2025 study showing that targeted insertion of a reporter gene at the rabbit CSN2 locus was associated with substantially higher milk protein concentrations than those commonly reported for conventional transgenic lines, while emphasizing the limits of reporter-based and historical comparisons.
What a Pharming Yield Result Really Means
2026-11-02
A reported 15–20 g/L recombinant-protein concentration in rabbit milk is striking, but its meaning depends on the reporter, genotype, measurement, and comparator. This editorial separates what the study demonstrates from what remains uncertain about therapeutic production, product quality, and generalizability.
Endogenous Promoters and High-Yield Pharming
2026-11-02
A mechanistic analysis of how targeting a recombinant transgene to the rabbit CSN2 milk-protein locus may increase expression, and what the reported data do—and do not—establish about yield, causality, and broader applicability.
When Context Changes a Result’s Meaning
2026-11-01
A mouse sepsis study used Diminazene Aceturate as a pharmacological probe of ACE2-linked cardiac protection, not as a general measure of its antiparasitic activity. The distinction clarifies what the findings establish, what the mitochondrial and cardiac readouts can support, and where model-specific and target-selectivity limits remain.